Abstract

LCIG (levodopa-carbidopa intestinal infusion) is an effective treatment option in advanced levodopa-responsive Parkinson’s disease. LCIG is indicated in the presence of motor fluctuations and hyper- and/or dyskinesias, which do not respond to oral levodopa treatment anymore. LCIG reduces OFF-time as monotherapy as well as polytherapy in combination with other antiparkinsonistic drugs. When choosing LCIG, the benefits of the treatment and the possible risks of side effects must be carefully considered.